Overall survival of lower-risk MDS patients predicted by total genomic alterations (TGA). Overall (A,C,E,F) and AML-free (B,D) survival was determined when patients were stratified by TGA (A,B,E) or IPSS score (C,D,F). Overall survival and AML-free survival of all patients (n = 40) as stratified by TGA (A,B) and IPSS score (C,D). Overall survival of patients with normal karyotype (n = 25) as stratified by TGA (E) and IPSS (F). Numbers in parentheses represent the number of patients in each group.